From July 1, 2022 to September 30, 2022, the company has repurchased 1,170,002 shares, representing 0.81% for $250 million. With this, the company has completed the repurchase of 11,254,007 shares, representing 7.51% for $2,950 million under the buyback announced on October 21, 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
190.5 USD | -0.85% | -6.46% | -26.37% |
Apr. 17 | UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating | MT |
Apr. 17 | Wedbush Cuts Biogen's Price Target to $213 From $245 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.37% | 27.93B | |
-5.32% | 84.57B | |
+3.95% | 39.93B | |
+52.09% | 24.21B | |
-6.59% | 17.17B | |
-32.37% | 13.93B | |
-10.45% | 12.3B | |
-15.88% | 11.84B | |
-2.85% | 7.91B | |
+0.53% | 7.48B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.